Francesca Maria Rossi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1647388/publications.pdf

Version: 2024-02-01

93 papers	3,166 citations	186265 28 h-index	168389 53 g-index
94 all docs	94 docs citations	94 times ranked	3864 citing authors

#	Article	IF	Citations
1	Elastin MIcrofibriL INterfacer1 (EMILINâ€1) is an alternative prosurvival VLAâ€4 ligand in chronic lymphocytic leukemia. Hematological Oncology, 2022, 40, 181-190.	1.7	3
2	Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. Haematologica, 2021, 106, 2345-2353.	3.5	8
3	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia, 2021, 35, 235-238.	7.2	17
4	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virusâ€related diseases. Liver International, 2021, 41, 133-149.	3.9	3
5	Comparison of ibrutinib and idelalisib plus rituximab in realâ€life relapsed/resistant chronic lymphocytic leukemia cases. European Journal of Haematology, 2021, 106, 493-499.	2.2	5
6	Assessment of the 4â€factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. American Journal of Hematology, 2021, 96, E168-E171.	4.1	10
7	<scp>TP53</scp> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 2021, 96, E306-E310.	4.1	8
8	Effectiveness of ibrutinib as firstâ€line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximabâ€bendamustine: Results of study on 486 cases outside clinical trials. American Journal of Hematology, 2021, 96, E269-E272.	4.1	3
9	TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2021, 27, 5566-5575.	7.0	23
10	COVIDâ€19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients. Hematological Oncology, 2021, 39, 712-714.	1.7	17
11	<i>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. Haematologica, 2021, 106, 3125-3135.	3.5	12
12	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisibâ€“rituximab. Blood Cancer Journal, 2020, 10, 92.	6.2	7
13	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. Blood, 2020, 135, 1244-1254.	1.4	33
14	Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica, 2020, 105, 448-456.	3.5	64
15	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. Haematologica, 2020, 105, 1613-1620.	3.5	15
16	Biallelic <scp>BIRC</scp>3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. British Journal of Haematology, 2019, 185, 156-159.	2.5	9
17	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. Haematologica, 2019, 104, e410-e414.	3.5	5
18	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia, 2019, 33, 2111-2115.	7.2	21

#	Article	IF	Citations
19	Clinical Impact of Clonal and Subclonal TP53 Mutations and Deletions in Chronic Lymphocytic Leukemia: An Italian Multicenter Experience. Blood, 2019, 134, 480-480.	1.4	12
20	The VLA-4 Integrin Is Constitutively Activated in a Fraction of CD49d-Expressing Chronic Lymphocytic Leukemia Via Autonomous BCR-Mediated Signaling. Blood, 2019, 134, 849-849.	1.4	0
21	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. Journal of Experimental Medicine, 2018, 215, 681-697.	8.5	65
22	<scp>NOTCH</scp>1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. British Journal of Haematology, 2018, 182, 597-602.	2.5	22
23	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clinical Cancer Research, 2018, 24, 120-129.	7.0	92
24	NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-ÎºB pathways. Leukemia, 2018, 32, 654-662.	7.2	31
25	Improved GMP compliant approach to manipulate lipoaspirates, to cryopreserve stromal vascular fraction, and to expand adipose stem cells in xeno-free media. Stem Cell Research and Therapy, 2018, 9, 130.	5.5	36
26	Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 4396-4396.	1.4	2
27	The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 4397-4397.	1.4	3
28	Intraclonal Diversification Occurs in Chronic Lymphocytic Leukemia Expressing B Cell Receptors Belonging to the IGHV4 Gene Family. Blood, 2018, 132, 944-944.	1.4	0
29	A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. Blood, 2018, 132, 4399-4399.	1.4	0
30	Mutations in the 3â€² untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia. Haematologica, 2017, 102, e305-e309.	3.5	18
31	NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. Leukemia, 2017, 31, 2407-2415.	7.2	52
32	Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. Haematologica, 2017, 102, e443-e446.	3.5	11
33	INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE. Hematological Oncology, 2017, 35, 109-110.	1.7	1
34	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia, 2016, 30, 2011-2018.	7.2	41
35	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. Haematologica, 2016, 101, 77-85.	3.5	53
36	THU0299â€…B Cell Compartment and Pharmacodynamics of Belimumab in Systemic Lupus Erythematosus: Early Clinical Efficacy by Depletion of CD27- and Increase of CD27+ B Cells: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 295.1-295.	0.9	0

#	Article	IF	Citations
37	NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. Leukemia, 2016, 30, 182-189.	7.2	74
38	Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia. Current Cancer Drug Targets, 2016, 16, 659-668.	1.6	11
39	CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34+ hemopoietic progenitors cells. Leukemia, 2014, 28, 705-708.	7.2	10
40	Ibrutinib-naÃ¯ve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. Blood, 2014, 124, 3831-3833.	1.4	27
41	Microenvironmental Interactions in Chronic Lymphocytic Leukemia: The Master Role of CD49d. Seminars in Hematology, 2014, 51, 168-176.	3.4	32
42	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Annals of Hematology, 2014, 93, 1765-1774.	1.8	34
43	Bendamustine Improves Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) According to Different Clinical and Biological Prognostic Factors. Blood, 2014, 124, 5668-5668.	1.4	1
44	NOTCH1 Mutations Are Associated with Low CD20 Expression in Chronic Lymphocytic Leukemia: Evidences for a NOTCH1-Mediated Epigenetic Regulatory Mechanism. Blood, 2014, 124, 296-296.	1.4	5
45	NOTCH1 Mutations Are Associated with High CD49d Expression in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 1978-1978.	1.4	0
46	Long term cryopreservation in 5% <scp>DMSO</scp> maintains unchanged <scp>CD</scp>34⁺ cells viability and allows satisfactory hematological engraftment after peripheral blood stem cell transplantation. Vox Sanguinis, 2013, 105, 77-80.	1.5	23
47	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood, 2013, 121, 1403-1412.	1.4	420
48	Clinical significance of c.7544â€7545 del<scp>CT </scp><scp>NOTCH</scp>1 mutation in chronic lymphocytic leukaemia. British Journal of Haematology, 2013, 160, 415-418.	2.5	14
49	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. Journal of Hematology and Oncology, 2013, 6, 83.	17.0	14
50	SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ. Molecular Cancer Therapeutics, 2013, 12, 1060-1072.	4.1	46
51	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood, 2013, 121, 4902-4905.	1.4	113
52	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood, 2013, 122, 3317-3321.	1.4	48
53	Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. Hematological Oncology, 2013, 31, 88-95.	1.7	25
54	CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. Haematologica, 2012, 97, 279-287.	3.5	32

#	Article	IF	Citations
55	CD49d Is Overexpressed in Trisomy 12 Chronic Lymphocytic Leukemia by an Epigenetic-Dependent Transcriptional Control. Blood, 2012, 120, 929-929.	1.4	1
56	Clinical Significance of NOTCH1 mutations in Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2870-2870.	1.4	0
57	Clinical Significance of 13q14 Number of Deleted Cells in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 4581-4581.	1.4	0
58	Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 712-712.	1.4	0
59	Cluster analysis of immunophenotypic data: The example of chronic lymphocytic leukemia. Immunology Letters, 2011, 134, 137-144.	2.5	17
60	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2011, 50, 633-643.	2.8	67
61	Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome. American Journal of Hematology, 2010, 85, 619-622.	4.1	10
62	A new freezing and storage procedure improves safety and viability of haematopoietic stem cells and neutrophil engraftment: a single institution experience. Vox Sanguinis, 2010, 98, 172-180.	1.5	13
63	Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. Clinical Cancer Research, 2010, 16, 620-628.	7.0	44
64	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. Leukemia and Lymphoma, 2010, 51, 95-106.	1.3	16
65	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. Journal of Translational Medicine, 2010, 8, 23.	4.4	19
66	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 3578-3578.	1.4	0
67	Normal Fish Cytogenetics and 13q Deletions Unveil Marked Biological and Clinical Heterogeneity In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 2692-2692.	1.4	0
68	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. Cancer Research, 2009, 69, 4001-4009.	0.9	153
69	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. British Journal of Haematology, 2009, 144, 492-506.	2.5	106
70	Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait. British Journal of Haematology, 2008, 141, 734-736.	2.5	21
71	Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. British Journal of Haematology, 2008, 142, 202-215.	2.5	206
72	CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. Haematologica, 2008, 93, 1575-1579.	3.5	72

#	Article	IF	Citations
73	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood, 2008, 111, 865-873.	1.4	226
74	Molecular, Phenotypic and Clinical Predictors of Richter Syndrome (RS) in Chronic Lymphocytic Leukemia (CLL).. Blood, 2007, 110, 3086-3086.	1.4	1
75	ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations. Cytometry Part B - Clinical Cytometry, 2006, 70B, 284-292.	1.5	38
76	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*. British Journal of Haematology, 2004, 125, 203-212.	2.5	26
77	Hyaluronanâ€“CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. Journal of Cell Biology, 2002, 158, 1133-1144.	5.2	83
78	Expression of Functional Interleukin-3 Receptors on Hodgkin and Reed-Sternberg Cells. American Journal of Pathology, 2002, 160, 585-596.	3.8	56
79	Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells. British Journal of Haematology, 2002, 117, 59-69.	2.5	10
80	CD30L up-regulates CD30 and IL-4 expression by T cells. FEBS Letters, 2001, 508, 418-422.	2.8	20
81	Normalizing Complementary DNA by Quantitative Reverse Transcriptaseâ€“Polymerase Chain Reaction of Î²2-Microglobulin: Molecular Monitoring of Minimal Residual Disease in Acute Promyelocytic Leukemia. Diagnostic Molecular Pathology, 2000, 9, 98-109.	2.1	19
82	CD30 Ligand (CD30L)-Expressing Acute Myeloid Leukemias: A New Model of Paracrine Interactions for the Regulation of Blast Cells Proliferation. Leukemia and Lymphoma, 1999, 35, 21-35.	1.3	11
83	Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. British Journal of Haematology, 1999, 104, 152-162.	2.5	22
84	The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up-regulated upon differentiation. British Journal of Haematology, 1999, 105, 225-240.	2.5	19
85	Frequent Expression of the Variant CD30 in Human Malignant Myeloid and Lymphoid Neoplasms. American Journal of Pathology, 1999, 155, 2029-2041.	3.8	21
86	Hodgkinâ€™s disease: A disorder of dysregulated cellular cross-talk. Biotherapy (Dordrecht,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 T	0.7	19
87	Differential expression of the RET gene in human acute myeloid leukemia. Annals of Hematology, 1998, 77, 207-210.	1.8	12
88	Competitive reverse-transcriptase PCR: a useful alternative to Northern blotting for quantitative estimation of relative abundances of specific mRNAs in precious samples. Biochemical Journal, 1997, 325, 565-567.	3.7	15
89	Practical Method for the Multigram Separation of the 5- and 6-Isomers of Carboxyfluorescein. Bioconjugate Chemistry, 1997, 8, 495-497.	3.6	37
90	CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin. Blood, 1997, 89, 2048-2059.	1.4	110

#	Article	IF	Citations
91	Flow Cytometric Technique for Quantitating Cytotoxic Response to Photodynamic Therapy. Photochemistry and Photobiology, 1996, 63, 111-116.	2.5	7
92	In vitro studies on the potential use of 5-aminolaevulinic acid-mediated photodynamic therapy for gynaecological tumours. British Journal of Cancer, 1996, 74, 881-887.	6.4	34
93	Photosensitizing activity of water- and lipid-soluble phthalocyanines on Escherichia coli. FEMS Microbiology Letters, 1990, 71, 149-156.	1.8	4